Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS

Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS

LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the…

Hansa Biopharma appoints Maria Törnsén as chief operating officer and US president - Pharmafile

Swedish biopharma company Hansa Biopharma has appointed Maria Törnsén as chief operating officer (COO) and president US effective 19 May 2025. Törnsén will report to CEO Renée Aguiar-Lucander and join the company’s executive committee. Törnsén brings more than 20 years of experience in global and US biopharma markets. She most recently served as president of […] The post Hansa Biopharma appoints Maria Törnsén as chief operating officer and US pr…